These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 4814143)

  • 1. Inhibition of mammary dysplasia in estrogen-treated C3H-HeJ female mice by treatment with 2-bromo-alpha-ergocryptine.
    Brooks CL; Welsch CW
    Proc Soc Exp Biol Med; 1974 Feb; 145(2):484-7. PubMed ID: 4814143
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of chronic treatment with 2-bromo-alpha-ergocryptine (CB-154) on the reproductive and lactational performance of the C3H/HeJ female mouse.
    Welsh CW; Morford LK
    Experientia; 1974 Nov; 30(11):1353-5. PubMed ID: 4435190
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of mammary tumorigenesis by ergot alkaloids and promotion of mammary tumorigenesis by pituitary isografts in adreno-ovariectomized mice.
    Yanai R; Nagasawa H
    J Natl Cancer Inst; 1972 Mar; 48(3):715-9. PubMed ID: 5058970
    [No Abstract]   [Full Text] [Related]  

  • 4. Prophylaxis of early preneoplastic lesions of the mammary gland.
    Welsch CW
    Cancer Res; 1976 Jul; 36(7 PT 2):2621-5. PubMed ID: 1277169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of DMBA-induced mammary carcinogenesis in the rat by 2-br- -ergocryptine (CB 154), an inhibitor of prolactin secretion, and by nafoxidine (U-11, 100 A), an estrogen antagonist.
    Heuson JC; Waelbroeck C; Legros N; Gallez G; Robyn C; L'Hermite M
    Gynecol Invest; 1971; 2(1):130-7. PubMed ID: 5170652
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of dietary fat, antiestrogen, and antiprolactin on the development of mammary tumors in rats.
    Chan PC; Cohen LA
    J Natl Cancer Inst; 1974 Jan; 52(1):25-30. PubMed ID: 4810966
    [No Abstract]   [Full Text] [Related]  

  • 7. 17beta-oestradiol and Enovid mammary tumorigenesis in C3H/HeJ female mice: counteraction by concurrent 2-bromo-alpha-ergocryptine.
    Welsch CW; Adams C; Lambrecht LK; Hassett CC; Brooks CL
    Br J Cancer; 1977 Mar; 35(3):322-8. PubMed ID: 576837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of mammary tumorigenesis in C3H/He mice by ovariectomy or treatment with 2-bromo-alpha-ergocryptine: a comparison.
    Welsch CW; Lambrecht LK; Hassett CC
    J Natl Cancer Inst; 1977 Apr; 58(4):1135-8. PubMed ID: 576623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct inhibition of pituitary LH secretion in rats by CB-154 (2-Br-alpha-ergocryptine).
    Seki M; Seki K; Yoshihara T; Watanabe N; Okumura T
    Endocrinology; 1974 Mar; 94(3):911-4. PubMed ID: 4591828
    [No Abstract]   [Full Text] [Related]  

  • 10. Prolactin and the development and progression of early neoplastic mammary gland lesions.
    Welsch CW
    Cancer Res; 1978 Nov; 38(11 Pt 2):4054-8. PubMed ID: 698954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis of spontaneously developing mammary carcinoma in C3H-HeJ female mice by suppression of prolactin.
    Welsch CW; Gribler C
    Cancer Res; 1973 Nov; 33(11):2939-46. PubMed ID: 4795906
    [No Abstract]   [Full Text] [Related]  

  • 12. Relation of prolactin and estrogen to mammary tumorigenesis in the rat.
    Meites J
    J Natl Cancer Inst; 1972 Apr; 48(4):1217-24. PubMed ID: 5023679
    [No Abstract]   [Full Text] [Related]  

  • 13. 6-Methyl-8-beta-ergoline-acetonitrile (MEA)-induced suppression of mammary tumorigenesis in C3H/HeJ female mice.
    Welsch CW; Gribler C; Clemens JA
    Eur J Cancer (1965); 1974 Sep; 10(9):595-600. PubMed ID: 4477735
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of chemopreventive agents on estradiol metabolism and mammary preneoplasia in the C3H mouse.
    Osborne MP; Telang NT; Kaur S; Bradlow HL
    Steroids; 1990 Mar; 55(3):114-9. PubMed ID: 2139751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of nursing on the release of prolactin and GH in mice with high and low incidence of mammary tumors.
    Sinha YN; Salocks CB; Lewis UJ; VanderLaan WP
    Endocrinology; 1974 Oct; 95(4):947-54. PubMed ID: 4472149
    [No Abstract]   [Full Text] [Related]  

  • 16. Interaction of estrogen and prolactin in spontaneous mammary tumorigenesis of the mouse.
    Welsch CW
    J Toxicol Environ Health Suppl; 1976; 1():161-75. PubMed ID: 1036505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition by ergocornine of initiation and growth of 7,12-dimethylbenzanthracene-induced mammary tumors in rats: effect of tumor size.
    Clemens JA; Shaar CJ
    Proc Soc Exp Biol Med; 1972 Feb; 139(2):659-62. PubMed ID: 5059060
    [No Abstract]   [Full Text] [Related]  

  • 18. Uterine and mammary neoplasia and other changes (amyloidosis) in C3H mice, related to ovariectomy, estrogen and methylcholanthrene.
    Wessely Z; Klavins JV
    Oncology; 1972; 26(1):33-52. PubMed ID: 4670914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Postpartal lactation inhibition by 2-Br-alpha-ergocryptine: II. A comparative study with 2-Br-alpha-ergocryptine and methallenoestrol (author's transl)].
    Varga L; Radielovic P
    Geburtshilfe Frauenheilkd; 1974 Oct; 34(10):885-7. PubMed ID: 4442688
    [No Abstract]   [Full Text] [Related]  

  • 20. Suppression of mammary hyperplastic nodule formation and pituitary prolactin secretion in mice induced by ergocornine or 2-bromo-a-ergocryptine.
    Yanai R; Nagasawa H
    J Natl Cancer Inst; 1970 Dec; 45(6):1105-12. PubMed ID: 5530649
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.